Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials. - Kimball, Alexa B; Jemec, Gregor B E; Alavi, Afsaneh; Reguiai, Ziad; Gottlieb, Alice B; Bechara, Falk G; Paul, Carle; Giamarellos Bourboulis, Evangelos J; Villani, Axel P; Schwinn, Andreas; Ruëff, Franziska; Pillay Ramaya, Larisha; et al. (Lancet, 2023)